Shukra Pharmaceuticals (BOM:524632) Construction In Progress: ₹119.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524632 Shukra Pharmaceuticals Ltd BOM:524632
66 GF Score
Price ₹33.09
GF Value ₹8.61
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Construction In Progress?

Shukra Pharmaceuticals BOM:524632 +9.97% 66 Construction In Progress is ₹119.1 Mil as of Mar. 2026. GuruFocus rates BOM:524632 with a GF Score™ of 66/100 and a GF Value™ of ₹8.61 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shukra Pharmaceuticals's quarterly construction in progress declined from Sep. 2025 (₹19.5 Mil) to Dec. 2025 (₹0.0 Mil) but then increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹119.1 Mil).

Shukra Pharmaceuticals's annual construction in progress increased from Mar. 2024 (₹20.2 Mil) to Mar. 2025 (₹23.1 Mil) and increased from Mar. 2025 (₹23.1 Mil) to Mar. 2026 (₹119.1 Mil).

Shukra Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Shukra Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shukra Pharmaceuticals Construction In Progress Chart

Shukra Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.60 16.62 20.23 23.07 119.07

Shukra Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.07 0.00 19.55 0.00 119.07
BOM:524632
66GF Score
Shukra Pharmaceuticals Ltd BOM:524632
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹119.1 Mil mean?
Shukra Pharmaceuticals (BOM:524632) has a Construction In Progress of ₹119.1 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' Construction In Progress too high?
Shukra Pharmaceuticals' current Construction In Progress is ₹119.1 Mil. Overall, Shukra Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Construction In Progress compare to ZTS?
Shukra Pharmaceuticals' Construction In Progress of ₹119.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current Construction In Progress is ₹119.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.61, compared to a current price of ₹33.09 — trading 284.3% above its estimated fair value. The current Construction In Progress is ₹119.1 Mil. Shukra Pharmaceuticals' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Construction In Progress is ₹119.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹33.09 is trading 284.3% above its estimated GF Value™ of ₹8.61. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524632:

  • Construction In Progress: ₹119.1 Mil
  • GF Value™: ₹8.61 vs. price of ₹33.09 (284.3% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
66GF Score

Get the complete analysis for BOM:524632

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹33.09
Price
₹8.61
GF Value